February 13, 2023 10:11 AM ESTUpdated 11:27 AM
R&D

Fre­quen­cy Ther­a­peu­tics re­ports tri­al fail and lays off over half of staff — stock cap­sizes

Lei Lei Wu

News Reporter

Fre­quen­cy Ther­a­peu­tics an­nounced Mon­day morn­ing that its lead can­di­date, a drug for hear­ing loss, failed a Phase IIb study. As a re­sult, the Lex­ing­ton, MA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times